The Institute of Medicine has identified the management of ductal carcinoma in situ (DCIS) as one of the highest priority topics for comparative effectiveness research. With the rise of mammographic screening, the incidence of DCIS has increased dramatically, and currently about a quarter of all newly diagnosed breast cancers are DCIS. Although DCIS is by definition noninvasive, treatment is ne...

Ductal carcinoma in situ (DCIS) is a subtype of breast cancer encountered increasingly in clinical practice because of the widespread use of screening mammography. In the present study, we evaluated the usefulness of breast-specific g-camera (BSGC) scintigraphy in DCIS identification, describing the scintigraphic findings and their correlation with mammography and histologic subtype. Methods: T...

In a typical breast surgery practice, nearly one-fifth of new patients present with ductal carcinoma in situ (DCIS), usually detected on mammography as an incidental finding. Most of these women are otherwise healthy, take care of themselves, have had a mammogram as part of their routine health maintenance, and are now grappling with a “cancer” diagnosis. When explaining to patients that DCIS g...

Gene expression patterns in ductal carcinoma in situ (DCIS), and in invasive, and metastatic breast tumors were determined using serial analysis of gene expression (SAGE). We used mRNA in situ hybridization to examine gene expression at the cellular level and immunohistochemistry on tissue microarrays to determine association between gene expression patterns and histopathologic characteristics ...

The aim of our research is to identify potential genes associated with Ductal carcinoma in situ (DCIS) through microarrays. The microarray dataset GS54665 were downloaded from the GEO(Gene Expression Omnibus) database. Dysregulated genes were screened and their associations with DCIS was analyzed by comprehensive bioinformatics tools. A total of 649 differential expression genes were identified...

OBJECTIVES Lymphovascular invasion (LVI) is a pathologic, microscopic finding associated with invasive cancer, and is a poor prognostic indicator, but has no reported imaging findings. This report presents the first documented case of LVI with seen by imaging. Linear branching microcalcifications were identified on mammography and clumped enhancement was noted on MRI, both imaging findings that...

Ductal carcinoma is situ (DCIS) is the fastest growing subtype of breast cancer, mainly because of improved screening activities. In contrast to invasive disease, DCIS is a local process with excellent survival rates. Current treatment strategies include surgery, radiotherapy (RT) and anti-hormonal treatment. The selection of an individual risk-adapted therapeutic approach remains controversial...

Breast cancer, when found in its early stages, is a manageable disease. When detected, biopsied, and diagnosed, lesions such as ductal carcinoma in-situ (DCIS) or invasive ductal carcinoma (IDC) are promptly removed. Consequently, the natural history of DCIS and IDC in-vivo is not well known. DCIS manifests itself with various distinctive patterns and pathologies. In order to study the growth d...

Here we present a series of infiltrative ductal carcinoma breast cases (infiltrative ductal carcinoma with central necrosis) so closely mimicking 'DCIS with central comedo necrosis' that on initial morphological analysis these foci of tumors were labeled as DCIS (high grade, comedo). However on further histological work up and by using immunohistochemistry (IHC) for myoepithelial markers it was...

OBJECTIVE To determine the rates of diagnostic underestimation at stereotactic percutaneous core needle biopsies (CNB) and vacuum-assisted biopsies (VABB) of nonpalpable breast lesions, with histopathological results of atypical ductal hyperplasia (ADH) or ductal carcinoma in situ (DCIS) subsequently submitted to surgical excision. As a secondary objective, the frequency of ADH and DCIS was det...